Product Description
Mechanisms of Action: TS Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Heidelberg Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Skin Cancer|Squamous Cell Carcinoma|Keratosis, Actinic|Melanoma|Keratosis|Colorectal Cancer|Breast Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2006-005525-33 | P2 |
Completed |
Keratosis, Actinic|Skin Cancer|Squamous Cell Carcinoma|Melanoma |
2008-01-09 |
|
| A Double-Blind Phase II Study of HDP 99.0006 in Patients with Actinic Keratosis | P2 |
Completed |
Keratosis |
2006-10-26 |
|
| 2005-001680-57 | P2 |
Completed |
Breast Cancer|Colorectal Cancer |
2006-09-22 |